問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of Infectious Disease

Division of General Internal Medicine

China Medical University Hospital (在職)

Division of Infectious Disease

更新時間:2023-09-19

施正蓮
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

29Cases

2012-02-01 - 2013-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-11-19 - 2023-05-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2015-09-01 - 2017-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial Pneumonia (CABP)
  • Condition/Disease

    The initial targeted indications are serious skin infections (ABSSSI), community acquired lower respiratory tract infections (CABP) and urinary tract infections

  • Test Drug

    Omadacycline (PTK 0796)

Participate Sites
5Sites

Terminated5Sites

2014-02-07 - 2015-07-30

Phase II/III

A Phase 3, multicenter, randomized, double-blind, active controlled study to evaluate the efficacy and safety of IV and oral delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections
  • Condition/Disease

    acute bacterial skin and skin structure infections

  • Test Drug

    Delafloxacin

Participate Sites
7Sites

Terminated7Sites

2011-11-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-03-31 - 2013-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Study ended5Sites

2012-09-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-01-01 - 2023-01-24

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-03-10 - 2020-09-22

Phase III

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment
  • Condition/Disease

    moderate COVID-19

  • Test Drug

    Remdesivir 100 mg

Participate Sites
3Sites

Terminated3Sites

1 2 3